频率感知可解释的深度学习框架用于阿尔茨海默氏症疾病分类使用rs-fMRI
Yutong Gao1, Robyn L Miller1, Vince D Calhoun1
1Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, GA, USA.
bioRxiv : the preprint server for biology
|September 26, 2025
概括
这项研究介绍了FINE,这是一种深度学习模型,用于分析阿尔茨海默病 (AD) 中的大脑连接模式. FINE识别了特定频率的干扰,为AD检测和理解疾病机制提供了新的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 人工智能的人工智能
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 诊断依赖于识别大脑连接的变化.
- 了解大脑网络的光谱和时间变化对于开发有效的生物标志物至关重要.
研究的目的:
- 介绍FINE (频率感知可解释神经编码器),这是一个新的深度学习模型.
- 从静态fMRI数据中捕获动态功能网络连接 (dFNC) 中的多尺度时间和频率特定模式.
- 为了提高阿尔茨海默病的分类,并提供可解释的洞察力,大脑连接的破坏.
主要方法:
- 开发了FINE,这是一个集卷积层,波形层,变压器和静态编码器的深度学习模型.
- 采用一个端到端的框架,共同建模时间演变和脑网络的光谱内容.
- 利用基于梯度的突出地图来进行频率智能解释,与统计组差异保持一致.
主要成果:
- 根据OASIS-3数据集 (856名受试者) 的评估,FINE获得了0.769的ROC-AUC,用于AD分类.
- 在皮下,感官运动和小脑网络中发现了特定频率的连接中断.
- 证明了该模型能够揭示潜在的强大,生物学上有意义的AD生物标志物的能力.
结论:
- 频率感知建模和可解释架构可以显著提升AD分类.
- FINE为AD相关大脑动态的功能性破坏提供了宝贵的见解.
- 这种方法有望开发出更具信息性的生物标志物,并加深对阿尔茨海默病机制的理解.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.6K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.4K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
